IP Library › Granted Patent US 12,310,993
Granted Patent B2
US 12,310,993 · App. 16/229,823 · Granted May 27, 2025

Human tissue derived compositions and uses thereof

Inventors: Steven Michael Sinclair (Ellicott City, MD); Alla Danilkovitch (Columbia, MD); Malathi Sathyamoorthy (Ellicott City, MD); Jin-Qiang Kuang (Glenelg, MD); Sandeep Dhall (Elkridge, MD); Yishan Liu (Doylestown, PA); Anthony John Melchiorri (Ellicott City, MD); Matthew Robert Moorman (Chestertown, MD); Mena Schiano Lo Moriello (Silver Spring, MD); Anne Allgood Lerch (Annapolis, MD)
A61K35/50A61K9/0014A61K9/0019A61K9/0024A61K9/06A61K9/19A61K35/33A61K35/51A61L26/0057A61L27/3604A61L27/3834A61P17/02A61P19/00A61P19/02A61P19/04A61P19/10A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,310,993
App. No.
16/229,823
Granted
May 27, 2025
Kind
B2
Abstract

Disclosed are compositions comprising a non-homogenized chorionic matrix, a homogenized amniotic matrix and a homogenized UC (UC) matrix, wherein the non-homogenized chorionic matrix comprises viable cells. Disclosed are methods of making the compositions disclosed herein comprising preparing a non-homogenized chorionic matrix, preparing a homogenized amniotic matrix, preparing a homogenized UC matrix, and combining the non-homogenized chorionic matrix, the non-homogenized chorionic matrix, and the homogenized UC matrix. Disclosed are methods of treating a tissue injury or chronic pain comprising administering any of the disclosed compositions to an area of a subject comprising a tissue injury.

Claims (20)

1. A composition comprising a minced chorionic matrix and a devitalized homogenized umbilical cord (UC) matrix,

wherein the minced chorionic matrix comprises native cells,

wherein the composition does not comprise trophoblasts or an amniotic matrix,

wherein the composition is lyophilized,

wherein at least 70% of the native cells of the minced chorionic matrix are viable after storage at room temperature in the lyophilized state,

wherein the minced chorionic matrix and the devitalized homogenized UC matrix are each in particulate form,

wherein the minced chorionic matrix has a larger average particle size than the devitalized homogenized UC matrix, and

wherein the devitalized homogenized UC matrix does not include Wharton's jelly.

2. The composition of claim 1 , wherein the composition is formulated as a cream, gel, oil, ointment, or lotion.

3. The composition of claim 1 further comprising viable, isolated amniotic cells.

4. The composition of claim 1 , wherein the homogenized UC matrix is not decellularized.

5. The composition of claim 1 , wherein the minced chorionic matrix is not homogenized.

6. The composition of claim 1 , wherein the composition comprises viable chorionic stem cells, amniotic stem cells, fibroblasts, epithelial cells or a combination thereof.

7. The composition of claim 1 , wherein the minced chorionic matrix and homogenized UC matrix are from the same donor.

8. The composition of claim 1 , wherein the homogenized UC matrix comprises de-veined UC tissue.

9. The composition of claim 1 , wherein the minced chorionic matrix comprises greater than or equal to 100,000 viable cells/ml.

10. The composition of claim 1 , wherein at least 75% of the native cells of the minced chorionic matrix are viable after storage at room temperature in the lyophilized state.

11. The composition of claim 1 , wherein the composition further comprises a pharmaceutically acceptable excipient.

12. The composition of claim 1 , wherein the homogenized UC matrix is 10 nm to 1 mm in size.

13. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2020
From: SINCLAIR, STEVEN MICHAEL; DANILKOVITCH, ALLA; SATHYAMOORTHY, MALATHI; KUANG, JIN-QIANG; DHALL, SANDEEP; LIU, YISHAN; MELCHIORRI, ANTHONY JOHN; MOORMAN, MATTHEW ROBERT; SCHIANO LO MORIELLO, MENA; ALLGOOD LERCH, ANNE
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 052038/0001 →
Continuity (3)
Division 15631707 · Jun 23, 2017
Provisional Application 62354466 · Jun 24, 2016
Related Publication 20190134099A1 · May 9, 2019
References Cited (42)
US 6962775B2 · Kuri-Harcuch et al. · 2005 [cited by applicant]
US 8231908B2 · Kinoshita et al. · 2012 [cited by applicant]
US 9956248B2 · Tom et al. · 2018 [cited by applicant]
US 10729809B2 · Uveges et al. · 2020 [cited by applicant]
US 20080069895A1 · Liu et al. · 2008 [cited by applicant]
US 20080131522A1 · Liu · 2008 [cited by examiner]
US 20120276581A1 · Arav · 2012 [cited by examiner]
US 20130216505A1 · Patel · 2013 [cited by examiner]
US 20140037598A1 · Jansen et al. · 2014 [cited by applicant]
US 20140212499A1 · Cooper et al. · 2014 [cited by applicant]
US 20140301986A1 · Tom et al. · 2014 [cited by applicant]
US 20150010506A1 · Jansen · 2015 [cited by examiner]
US 20150010610A1 · Tom et al. · 2015 [cited by applicant]
US 20150231183A1 · Peterson et al. · 2015 [cited by applicant]
US 20150335686A1 · Spencer · 2015 [cited by examiner]
US 20150342998A1 · Tseng · 2015 [cited by examiner]
US 20160030635A1 · Bhatia et al. · 2016 [cited by applicant]
US 20170368105A1 · Sinclair et al. · 2017 [cited by applicant]
US 20190134099A1 · Sinclair et al. · 2019 [cited by applicant]
US 20200230176A1 · Tom et al. · 2020 [cited by applicant]
WO WO9745009 · 1997 [cited by applicant]
WO WO2008021391B1 · 2008 [cited by applicant]
WO WO2011031489 · 2011 [cited by applicant]
WO WO2011103446 · 2011 [cited by applicant]
WO WO2016033041 · 2016 [cited by applicant]
WO WO2017223494 · 2017 [cited by applicant]
Rodriguez-Ares et al. “Effects of lyophilization on human amniotic membrane” Act Ophthalmologica 2009: 87: 396-403 (Year: 2009). [cited by examiner]
Parolini, O. et al., Concise Review: Isolation and Characterization of Cells from Human Term Placenta: Outcome of the First International Workshop on Placenta Derived Stem Cells. Stem Cells. 2008; 26(2): 300-11. [cited by applicant]
Portmann-Lanz, C.B. et al., Placental Mesenchymal Stem Cells as Potential Autologous Graft for Pre- and Perinatal Neuroregeneration. Am J Obstet Gynecol. 2006; 194: 664-73. [cited by applicant]
Socini, M. et al., Isolation and Characterization of Mesenchymal Cells from Human Fetal Membranes. J Tissue Eng Regen Med. 2007; 1(4): 296-305. [cited by applicant]
International Search Report and Written Opinion mailed on Sep. 14, 2017 by the International Searching Authority for International Patent Application No. PCT/US2017/039075, which was filed on Jun. 23, 2017 and published… [cited by applicant]
International Preliminary Report on Patentabilty issued on Dec. 25, 2018 by the International Searching Authority for International Patent Application No. PCT/US2017/039075, which was filed on Jun. 23, 2017 and publishe… [cited by applicant]
Restriction Requirement issued on Oct. 1, 2018 by the U.S. Patent and Trademark Office for U.S. Appl. No. 15/631,707, which was filed Jun. 23, 2017 and published as US 2017/0368105 on Dec. 28, 2017 (Inventor—Sinclair et… [cited by applicant]
Non-Final Office Action issued on Mar. 7, 2019 by the U.S. Patent and Trademark Office for U.S. Appl. No. 15/631,707, which was filed Jun. 23, 2017 and published as US 2017/0368105 on Dec. 28, 2017 (Inventor—Sinclair et… [cited by applicant]
Cooke, et al. “Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue,” [cited by applicant]
Duan-Arnold, et al. “Retention of Endogenous Viable Cells Enhances the Anti-Inflammatory Activity of Cryopreserved Amnion,” [cited by applicant]
Extended European Search Report issued in corresponding European Patent Application No. 17816324.2, dated Dec. 5, 2019. [cited by applicant]
Extended European Search Report issued in corresponding European Patent Application No. 17816341.6, dated Dec. 2, 2019. [cited by applicant]
International Search Report and Written Opinion mailed on Sep. 25, 2017 by the International Searching Authority for International Patent Application No. PCT/US2017/039123, which was filed on Jun. 23, 2017 (Applicant—Os… [cited by applicant]
Roti et al., “Cellular responses to hyperthermia (40-46C): Cell killing and molecular events” [cited by applicant]
Office Action issued in corresponding U.S. Appl. No. 17/698,490, dated Jul. 19, 2023. [cited by applicant]
International Search Report issued in corresponding PCT Application No. PCT/US2021/022059, dated Jul. 12, 2021. [cited by applicant]